ArticleClinical and vaccine immunology : CVI2013
A novel line immunoassay based on recombinant virulence factors enables highly specific and sensitive serologic diagnosis of Helicobacter pylori infection.
Article in Clinical and vaccine immunology : CVI, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- First regional consensus on the management ofWorld journal of gastroenterology · 2025Guideline
- Non-invasive diagnostic tests for Helicobacter pylori infection.The Cochrane database of systematic reviews · 2018Pooled it
- Potential pathogenesis ofFuture science OA · 2026Article
- Conventional Upper-Intestinal Endoscopy Value in Predicting Histopathological Features Related toJGH open : an open access journal of gastroenterology and hepatology · 2025Article
- Is Helicobacter pylori infection a risk factor for non-alcoholic fatty liver disease in children?European journal of pediatrics · 2024Article
- The chimeric UreB, FliD and Omp18 proteins for a sensitive and specific diagnosis ofIranian journal of microbiology · 2024Article
- RecombinantAntibiotics (Basel, Switzerland) · 2022Review
- Helicobacter pylori Infection, Its Laboratory Diagnosis, and Antimicrobial Resistance: a Perspective of Clinical Relevance.Clinical microbiology reviews · 2022Review
- Serodiagnosis and Bacterial Genome ofToxins · 2021Article
- Analysis of recombinant proteins for Q fever diagnostics.Scientific reports · 2020Article
- Article
- Epitope peptides of Helicobacter pylori CagA antibodies from sera by whole-peptide mapping.Journal of gastroenterology · 2019Article
- Differences inJournal of clinical biochemistry and nutrition · 2019Article
- Validation of a Blood Biomarker for Identification of Individuals at High Risk for Gastric Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2018Article
- Article
- Development of a Bead-Based Multiplex Assay for the Analysis of the Serological Response against the Six Pathogens HAV, HBV, HCV, CMV, T. gondii, and H. pylori.High-throughput · 2017Article
- Performance of a Multiplex Serological Helicobacter pylori Assay on a Novel Microfluidic Assay Platform.Proteomes · 2017Article
- Cut-off optimization forScientific reports · 2017Article
- Article
- Validation of a Novel Immunoline Assay for Patient Stratification according to Virulence of the InfectingJournal of immunology research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Helicobacter pylori colonizes half of the world's population, and infection can lead to ulcers, gastric cancer, and mucosa-associated lymphoid tissue (MALT) lymphoma. Serology is the only test applicable for large-scale, population-based screening, but current tests are hampered by a lack of sensitivity and/or specificity. Also, no serologic test allows the differentiation of type I and type II strains, which is important for predicting the clinical outcome. H. pylori virulence factors have been associated with disease, but direct assessment of virulence factors requires invasive methods to obtain gastric biopsy specimens. Our work aimed at the development of a highly sensitive and specific, noninvasive serologic test to detect immune responses to important H. pylori virulence factors. This line immunoassay system (recomLine) is based on recombinant proteins. For this assay, six highly immunogenic virulence factors (CagA, VacA, GroEL, gGT, HcpC, and UreA) were expressed in Escherichia coli, purified, and immobilized to nitrocellulose membranes to detect serological immune responses in patient's sera. For the validation of the line assay, a cohort of 500 patients was screened, of which 290 (58.0%) were H. pylori negative and 210 (42.0%) were positive by histology. The assay showed sensitivity and specificity of 97.6% and 96.2%, respectively, compared to histology. In direct comparison to lysate blotting and enzyme-linked immunosorbent assay (ELISA), the recomLine assay had increased discriminatory power. For the assessment of individual risk for gastrointestinal disease, the test must be validated in a larger and defined patient cohort. Taking the data together, the recomLine assay provides a valuable tool for the diagnosis of H. pylori infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.